Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction.

Senescent cells accumulate in a variety of tissues with aging. They can develop a senescence-associated secretory phenotype (SASP) that entails secretion of inflammatory cytokines, chemokines, proteases, and growth factors. These SASP components can alter the microenvironment within tissues and affect the function of neighboring cells, which can eventually lead to local and systemic dysfunction. The JAK pathway is more highly activate in senescent than non-senescent cells. Inhibition of the JAK pathway suppresses the SASP in senescent cells and alleviates age-related tissue dysfunction. Targeting senescent cells could be a promising way to improve healthspan in aged population.

[1]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[2]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[3]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[4]  E. Mercken,et al.  Metformin improves healthspan and lifespan in mice , 2013, Nature Communications.

[5]  A. Christiano,et al.  Pharmacologic inhibition of JAK-STAT signaling promotes hair growth , 2015, Science Advances.

[6]  Kelly J. Morris,et al.  A complex secretory program orchestrated by the inflammasome controls paracrine senescence , 2013, Nature Cell Biology.

[7]  Manuel Serrano,et al.  Cellular senescence: from physiology to pathology , 2014, Nature Reviews Molecular Cell Biology.

[8]  H. Pircher,et al.  Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.

[9]  A. Oberg,et al.  Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice , 2014, Aging.

[10]  N. LeBrasseur,et al.  Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders , 2011, Nature.

[11]  J. Campisi,et al.  Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. , 2013, The Journal of clinical investigation.

[12]  S. Rane,et al.  JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. , 1994, Oncogene.

[13]  A. Melk,et al.  Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening. , 2003, Kidney international.

[14]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[15]  Leslie A. Smith,et al.  Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice , 2016, Aging cell.

[16]  V. Paradis,et al.  Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. , 2001, Human pathology.

[17]  John J. O’Shea,et al.  Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.

[18]  C. Lawless,et al.  A senescent cell bystander effect: senescence-induced senescence , 2012, Aging cell.

[19]  D. Kurz,et al.  Cellular senescence in vivo: Its relevance in ageing and cardiovascular disease , 2005, Experimental Gerontology.

[20]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[21]  Nicolas A. Dumont,et al.  Inhibition of JAK/STAT signaling stimulates adult satellite cell function , 2014, Nature Medicine.

[22]  M. Jensen,et al.  Fat tissue, aging, and cellular senescence , 2010, Aging cell.

[23]  J. Hoeijmakers,et al.  An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. , 2014, Developmental cell.

[24]  N. LeBrasseur,et al.  Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity , 2015, Diabetes.

[25]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[26]  J. Kirkland,et al.  Clinical strategies and animal models for developing senolytic agents , 2015, Experimental Gerontology.

[27]  A. Poulsen,et al.  SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies , 2011, Leukemia.

[28]  J. Fridman,et al.  Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.

[29]  P. Nelson,et al.  MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation , 2015, Nature Cell Biology.

[30]  L. Hayflick,et al.  The serial cultivation of human diploid cell strains. , 1961, Experimental cell research.

[31]  N. LeBrasseur,et al.  Cellular Senescence and the Biology of Aging, Disease, and Frailty. , 2015, Nestle Nutrition Institute workshop series.

[32]  M. Shibamori,et al.  Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. , 2000, Immunity.

[33]  A. Klochendler,et al.  p16Ink4a-induced senescence of pancreatic beta cells enhances insulin secretion , 2016, Nature Medicine.

[34]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. E. Hughes,et al.  Glucocorticoids suppress selected components of the senescence‐associated secretory phenotype , 2012, Aging cell.

[36]  H. Fuchs,et al.  Rapamycin extends murine lifespan but has limited effects on aging. , 2013, The Journal of clinical investigation.

[37]  A. Pezeshki,et al.  Naturally occurring p16Ink4a-positive cells shorten healthy lifespan , 2016, Nature.

[38]  M. Cesari,et al.  Proinflammatory cytokines, aging, and age-related diseases. , 2013, Journal of the American Medical Directors Association.

[39]  P. Pandolfi,et al.  Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. , 2014, Cell reports.

[40]  M. Jensen,et al.  Targeting senescent cells enhances adipogenesis and metabolic function in old age , 2015, eLife.

[41]  G. Nelson,et al.  DNA damage response and cellular senescence in tissues of aging mice , 2009, Aging cell.

[42]  R. Stuart,et al.  Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside , 2010, Expert opinion on investigational drugs.

[43]  G. Ferbeyre,et al.  Metformin inhibits the senescence‐associated secretory phenotype by interfering with IKK/NF‐κB activation , 2013, Aging cell.

[44]  M. Jensen,et al.  JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age , 2015, Proceedings of the National Academy of Sciences.

[45]  N. LeBrasseur,et al.  The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs , 2015, Aging cell.

[46]  R. Levine,et al.  Molecular Pathways Molecular Pathways : Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors , 2014 .

[47]  D. Peeper,et al.  Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network , 2008, Cell.

[48]  Allison J. Richard,et al.  Emerging roles of JAK–STAT signaling pathways in adipocytes , 2011, Trends in Endocrinology & Metabolism.

[49]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[50]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.